KIRKLAND, Wash., Dec. 9, 2013 /PRNewswire/ -- "As we continue to focus on engineering the safer pharmacy, we constantly evaluate what we view as 'Best of Breed' Integration Partners to extend the products and solutions we deliver to our customers," said Carla Corkern, Chief Executive Officer of Talyst. "We have found that with GRIFOLS, and their Phocus Rx®, Remote IV Compounding Validation product. Talyst has reached an agreement to sell the Phocus Rx® product to existing and new customers." Phocus Rx® is the only non-invasive camera system designed for use in compounding area with any type of hood or open compounding environment.
"We look forward to working with the GRIFOLS team in integrating their Phocus Rx® product into Talyst's AutoPharm Enterprise Solution, as we both continue to focus on enhanced workflow efficiency, and improved patient safety," said Scott Starke, General Manager of Talyst's Acute Care business segment.
"GRIFOLS is proud to be a part of this initiative," said Juan M. Cana, General Manager of GRIFOLS USA Hospital Division. "Throughout the following years, we look forward to collaborating with the Talyst team in providing technology systems specially designed to enhance efficiency and increase the safety of sterile preparations in hospital pharmacy."
Talyst is a leader in pharmacy automation and engineers the safer pharmacy. Our solutions provide enterprise-wide medication management across your entire health system to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2013, Talyst has installed automated systems in more than 700 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. We offer a powerful software platform with a suite of hardware components to meet your specific needs. Follow us on Twitter @Talyst_Inc or visit us at http://www.talyst.com.
GRIFOLS is a global healthcare company with a 70-year legacy of improving people's health and well-being through the development of life-saving plasma medicines, hospital pharmacy products, and diagnostic technology for clinical use. GRIFOLS USA Hospital Division provides simple, cost-effective solutions to operational challenges in pharmacy. Its primary focus is on the sterile IV preparation area. Providing a wide range of hardware, software and disposable products for hospital pharmacies, GRIFOLS develops technology systems designed to increase the safety of sterile preparations and clean room solutions in pharmacy settings.
In 2012, GRIFOLS' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they form part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.